Dr. Nathan Lack obtained his DPhil (PhD) in Pharmacology from the University of Oxford in 2009 and then did a Postdoctoral Fellowship at the Vancouver Prostate Centre with Dr. Emma Guns and Professor Paul Rennie. Nathan became an Assistant Professor at Koç University in the School of Medicine in 2011 and was awarded Associate Professorship in 2015. He has a cross-academic appointment at the University of British Columbia and is a Senior Research Scientist at the Vancouver Prostate Cancer. In addition to his academic research, Nathan previously worked for AnorMED Inc., where he was involved in the development of the FDA-approved therapeutic Plerixafor.
His laboratory works to better understand the molecular underpinnings of prostate cancer to develop more effectively treatments for this common disease. Extensive clinical and basic research has shown that Androgen Receptor (AR)-mediated transcription drives the proliferation and growth of almost all prostate cancers. His group currently studies a diverse group of problems related to AR signaling including:
- Identification of small molecule AR inhibitors that target novel sites
- Characterization of non-coding mutations that affect androgen receptor signalling
- Development of novel functional genomic techniques to study AR-mediated transcription
For additional information please see https://lacklab.ku.edu.tr